[Strontium-89 diagnosis and therapy of bone metastases].
A clinical test of strontium-89 chloride effect was carried out in 150 patients with bone metastases and bone pain from different patterns of tumor. Different types of bone lesions were considered. Pain-relieving effect was reported in 77%, irrespective of lesion gravity. There was no response to strontium-89 chloride in 150 patients with bone metastases. It mostly occurred in cases of lysis. Strontium-89 chloride therapy contributed to partial bone tissue repair. It is indicated as a component of complex treatment for bone metastases.
Ryzhkov
A D
AD
Gabuniia
R I
RI
Kochergina
N V
NV
Shiriaev
S V
SV
Zimina
O G
OG
D000700:Analgesics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D011471:Prostatic Neoplasms / Q000473:pathology; D011877:Radionuclide Imaging; D013324:Strontium / Q000627:therapeutic use*; D013326:Strontium Radioisotopes
D000700:Analgesics; D000970:Antineoplastic Agents; D013326:Strontium Radioisotopes; C025700:strontium chloride; D013324:Strontium